江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP Mediaroom

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical...

2024-02-21 12:26 1840

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group L...

2023-11-23 16:04 4079

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company

-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total r...

2023-04-24 18:09 2017

Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simc...

2023-03-14 20:00 2194

First Prescription for COSELA® (trilaciclib) Issued in China

- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital...

2023-02-09 21:00 2595

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced toda...

2022-12-20 19:21 1793

Simcere and Idorsia enter into a licensing agreement for daridorexant in China

NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere")...

2022-11-16 08:32 2995

Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237

Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oc...

2022-10-27 21:25 1951

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

* Simcere will receive a $15 million upfront payment, and up to $492 million in development and c...

2022-09-29 11:32 1246

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue

NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announ...

2022-09-05 13:09 3324

Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group

NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appo...

2022-09-05 13:08 2255

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candida...

2022-05-18 11:56 1967

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day

NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK),...

2022-04-19 10:28 1820

SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

HONG KONG, April 7, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pha...

2022-04-07 21:39 2278

SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK...

2022-02-24 13:34 1474

Simcere Pharma (2096.HK) Announces a Positive Profit Alert

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", toget...

2022-02-23 16:22 2911

Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

NANJING, China, Feb. 7, 2022 /PRNewswire/ -- Simcere is thrilled to announce Bijoyesh Mookerjee, M....

2022-02-08 10:01 1642

Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments

NANJING, China, Nov. 22, 2021 /PRNewswire/ -- On November 17, 2021, Simcere Pharmaceutical Group Li...

2021-11-23 11:22 1732

Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China

NANJING, China and SEOUL, South Korea, Sept. 27, 2019 /PRNewswire/ -- Simcere Pharmaceutical Group ...

2019-09-27 18:52 4372

Latest News